EUAs, partnerships, etc all take time. Average dea
Post# of 1418
(Total Views: 233)
Posted On: 04/23/2022 11:15:13 AM
Re: jamesfranklin #829
EUAs, partnerships, etc all take time. Average deals I work on take at least 6 months and I'm not in pharma nor do I have to deal with turtle slow governments.
Don't lose sight there is a lot of money to be made with Tollovid. We are now 5 months into the T-Cell Protect Hellas deal and it sounds like they just got EU approval. What is interesting that we learned is doctors will be prescribing it as an approved anti-viral that people will pick up from their pharmacists.
It that Tollovid MAX and they'll continue to sell Tollovid on their website? Don't know.
Notice this on the T-Cell Website...
Anti-Viral & Anti-Inflammatory
Stop Infections From Replicating With the ONLY 3CL Protease Inhibitor Available Over the Counter!
https://www.tcellprotect.com/
Keep in mind revenue projections have increased. Whether that is because of testing, Tollovid sales, EUAs, I'm happy to wait to see. More important thing is Todos feel confident in revenue this year to more than double it.
The other interesting thing on the call was @32:30 getting valuations and 'closing' on the 3CL Pharma 'transaction'
To me, it sure sounds like a big deal is in the works to fund 3CL Pharma. Should come as a surprise since it is in the agreements with NCL Pharma on March 17th.
To put things into perspective, the closing of the 3CL Pharma deal with NCL only happened 5 weeks ago. Some companies put together a historic timeline so investors can see everything that happened as there sure has been a lot over the last 4-5 months that I see.
Oh and we should get an update on Lympro this quarter.
122 bottles left of Tollovid Daily left on Amazon. Get it while it's hot.
Earlier this week, there were slightly more before it quickly sold out.
Don't lose sight there is a lot of money to be made with Tollovid. We are now 5 months into the T-Cell Protect Hellas deal and it sounds like they just got EU approval. What is interesting that we learned is doctors will be prescribing it as an approved anti-viral that people will pick up from their pharmacists.
It that Tollovid MAX and they'll continue to sell Tollovid on their website? Don't know.
Notice this on the T-Cell Website...
Anti-Viral & Anti-Inflammatory
Stop Infections From Replicating With the ONLY 3CL Protease Inhibitor Available Over the Counter!
https://www.tcellprotect.com/
Keep in mind revenue projections have increased. Whether that is because of testing, Tollovid sales, EUAs, I'm happy to wait to see. More important thing is Todos feel confident in revenue this year to more than double it.
The other interesting thing on the call was @32:30 getting valuations and 'closing' on the 3CL Pharma 'transaction'
To me, it sure sounds like a big deal is in the works to fund 3CL Pharma. Should come as a surprise since it is in the agreements with NCL Pharma on March 17th.
To put things into perspective, the closing of the 3CL Pharma deal with NCL only happened 5 weeks ago. Some companies put together a historic timeline so investors can see everything that happened as there sure has been a lot over the last 4-5 months that I see.
Oh and we should get an update on Lympro this quarter.
122 bottles left of Tollovid Daily left on Amazon. Get it while it's hot.
Earlier this week, there were slightly more before it quickly sold out.
(2)
(0)Todos Med Ltd. (TOMDF) Stock Research Links
Scroll down for more posts ▼